Last reviewed · How we verify
Exenatide 2 MG
At a glance
| Generic name | Exenatide 2 MG |
|---|---|
| Also known as | Bydureon, Bydureon Pen, 2 Mg, Extended Release, Bydureon BCise, Byetta |
| Sponsor | Peking Union Medical College Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis (PHASE2)
- Exenatide for Smoking Cessation and Prevention of Weight Gain (PHASE2)
- Exenatide For Reducing the Reinforcing Effects of Cocaine (PHASE1)
- Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome (PHASE3)
- Diabetes Islet Preservation Immune Treatment (PHASE1, PHASE2)
- Brain Activation and Satiety in Children 2 (PHASE3)
- Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
- Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |